Abstract
Malignant glioma is a primary tumor of the central nervous system, representing a major cause of mortality in a young, productive subset of population. The management of this neoplasm requires aggressive treatments, including radiotherapy. Accurate imaging plays a central role in treatment planning process with curative intent based on radiation therapy. In order to maximize the radiation dose to the tumor and to minimize the damage to the normal surrounding tissue, a reliable identification of viable tumor margins is indeed required. The use of PET in the treatment planning process has become more promising over the years, although many important questions must be addressed. The aim of this article is to critically review the evidence supporting PET in radiotherapy planning, with special emphasis on the role of novel radiopharmaceuticals, comparing its sensitivity and specificity with respect to 18F-FDG and other anatomic imaging modalities.
Keywords: Glioblastoma, PET, radiotherapy, target volume, treatment planning.
Current Pharmaceutical Biotechnology
Title:The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma
Volume: 14 Issue: 13
Author(s): Giulia Marvaso, Agnese Barone, Nicola Amodio, Giuseppe L. Cascini, Valerio Scotti and Cataldo Bianco
Affiliation:
Keywords: Glioblastoma, PET, radiotherapy, target volume, treatment planning.
Abstract: Malignant glioma is a primary tumor of the central nervous system, representing a major cause of mortality in a young, productive subset of population. The management of this neoplasm requires aggressive treatments, including radiotherapy. Accurate imaging plays a central role in treatment planning process with curative intent based on radiation therapy. In order to maximize the radiation dose to the tumor and to minimize the damage to the normal surrounding tissue, a reliable identification of viable tumor margins is indeed required. The use of PET in the treatment planning process has become more promising over the years, although many important questions must be addressed. The aim of this article is to critically review the evidence supporting PET in radiotherapy planning, with special emphasis on the role of novel radiopharmaceuticals, comparing its sensitivity and specificity with respect to 18F-FDG and other anatomic imaging modalities.
Export Options
About this article
Cite this article as:
Marvaso Giulia, Barone Agnese, Amodio Nicola, Cascini L. Giuseppe, Scotti Valerio and Bianco Cataldo, The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma, Current Pharmaceutical Biotechnology 2013; 14 (13) . https://dx.doi.org/10.2174/1389201015666140408122318
DOI https://dx.doi.org/10.2174/1389201015666140408122318 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology CPP-Based Bioactive Drug Delivery to Penetrate the Blood-Brain Barrier: A Potential Therapy for Glioblastoma Multiforme
Current Drug Targets Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Antiangiogenic Therapy
Current Pharmaceutical Design Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Current Pharmaceutical Design Graphene Family of Nanomaterials: Reviewing Advanced Applications in Drug delivery and Medicine
Current Drug Delivery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Incorporating Link Information in Feature Selection for Identifying Tumor Biomarkers by Using miRNA-mRNA Paired Expression Data
Current Proteomics Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art
Current Neuropharmacology Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Equinatoxin II Potentiates Temozolomide- and Etoposide-Induced Glioblastoma Cell Death
Current Topics in Medicinal Chemistry NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets